Clinical Trials Logo

Metastatic Carcinoma clinical trials

View clinical trials related to Metastatic Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02192346 Completed - Metastatic Sarcoma Clinical Trials

α-TEA in Advanced Cancer

Start date: August 4, 2014
Phase: Phase 1
Study type: Interventional

The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood. Additional goals of this study are to monitor the effect on tumors, to check for specific immune cells circulating in the blood, and to see if there are certain features of tumors that make it possible to predict the response to α-TEA.

NCT ID: NCT01469598 Completed - Clinical trials for Metastatic Carcinoma

Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

Start date: August 2011
Phase: Phase 2
Study type: Interventional

Gemcitabine is a novel analog of the nucleoside deoxycytidine that acts via inhibition of DNA synthesis.Docetaxel is a semisynthetic taxane and promotes microtubule assembly and inhibits microtubule depolymerization. In this study, patients received gemcitabine 900 mg/m2 on days 1 and 8 plus docetaxel 100 mg/m2 on day 8 with G-CSF support every 3 week.

NCT ID: NCT01320241 Completed - Pancreatic Cancer Clinical Trials

Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture

Start date: November 2008
Phase: Phase 2
Study type: Interventional

Malignant biliary obstruction is a common clinical condition caused by various malignancies. Currently,biliary stent implantation guided either by fluoroscopy or endoscopy has become the most important methods for relieving malignant biliary obstruction. However, the benefit for the survival of the patients with palliation of the stent treatment is limited because no therapeutic effects on process of the tumor itself by a stent implantation. Encouraged by the success of 125I esophageal stent in esophageal carcinoma, a novel biliary stent loaded with 125I radioactive seeds has been developed in our institute. After ex vivo and in vivo evaluations for the delivery system, the investigators prospectively compare the responses to treatment with this radiation biliary stent, versus the conventional biliary SEMS in patient with malignant biliary obstruction.